Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection

• Egile Nagusiak: Ana Castro-Balado (Egilea), Cristina Mondelo-García (Egilea), Letricia Barbosa-Pereira (Egilea), Iria Varela-Rey (Egilea), Ignacio Novo-Veleiro (Egilea), Néstor Vázquez-Agra (Egilea), José Ramón Antúnez-López (Egilea), Enrique José Bandín-Vilar (Egilea), Raquel Sendón-García (Egilea), Manuel Busto-Iglesias (Egilea), Ana Rodríguez-Bernaldo de Quirós (Egilea), Laura García-Quintanilla (Egilea), Miguel González-Barcia (Egilea), Irene Zarra-Ferro (Egilea), Francisco J. Otero-Espinar (Egilea), David Rey-Bretal (Egilea), José Ramón Lago-Quinteiro (Egilea), Luis Valdés-Cuadrado (Egilea), Carlos Rábade-Castedo (Egilea), María Carmen del Río-Garma (Egilea), Carlos Crespo-Diz (Egilea), Olga Delgado-Sánchez (Egilea), Pablo Aguiar (Egilea), Gema Barbeito-Castiñeiras (Egilea), María Luisa Pérez del Molino-Bernal (Egilea), Rocío Trastoy-Pena (Egilea), Rossana Passannante (Egilea), Jordi Llop (Egilea), Antonio Pose-Reino (Egilea), Anxo Fernández-Ferreiro (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2021-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Inhaled administration of ethanol in the early stages of COVID-19 would favor its location on the initial replication sites, being able to reduce the progression of the disease and improving its prognosis. Before evaluating the efficacy and safety of this novel therapeutic strategy in humans, its ch...